Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Total Liabilities
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has total liabilities worth CN¥691.49 Million CNY (≈ $101.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chengdu Easton Biopharmaceuticals Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Chengdu Easton Biopharmaceuticals Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
USA | $91.35 Million |
|
Red Star Macalline Group Corp Ltd Class A
SHG:601828
|
China | CN¥67.39 Billion |
|
Jutze Intelligent Technology Co Ltd
SHE:300802
|
China | CN¥391.11 Million |
|
TTW Public Company Limited
BK:TTW
|
Thailand | ฿6.82 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
China | CN¥1.47 Billion |
|
Pennant Group Inc
NASDAQ:PNTG
|
USA | $567.05 Million |
|
Reit 1
TA:RIT1
|
Israel | ILA4.85 Billion |
|
Corbion NV
AS:CRBN
|
Netherlands | €674.30 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Easton Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below shows the annual total liabilities of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-2.87 Billion ≈ $-419.38 Million |
-508.14% |
| 2024-12-31 | CN¥702.21 Million ≈ $102.75 Million |
-5.53% |
| 2023-12-31 | CN¥743.33 Million ≈ $108.77 Million |
+29.71% |
| 2022-12-31 | CN¥573.08 Million ≈ $83.86 Million |
+18.50% |
| 2021-12-31 | CN¥483.60 Million ≈ $70.77 Million |
+11.02% |
| 2020-12-31 | CN¥435.61 Million ≈ $63.74 Million |
+50.40% |
| 2019-12-31 | CN¥289.64 Million ≈ $42.38 Million |
+39.58% |
| 2018-12-31 | CN¥207.50 Million ≈ $30.36 Million |
+41.45% |
| 2017-12-31 | CN¥146.70 Million ≈ $21.47 Million |
+12.48% |
| 2016-12-31 | CN¥130.43 Million ≈ $19.09 Million |
+200.42% |
| 2015-12-31 | CN¥43.42 Million ≈ $6.35 Million |
-45.63% |
| 2014-12-31 | CN¥79.85 Million ≈ $11.68 Million |
-7.42% |
| 2013-12-31 | CN¥86.24 Million ≈ $12.62 Million |
-- |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more